Please assess the completion status of the following clinical trial:

Trial Title: Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~A woman between, and including, 10 and 14 years of age at the time of the first vaccination.~Written informed consent from the subject prior to enrolment. Subject must be free of obvious health problems. Subject must have negative urine pregnancy test.~Exclusion Criteria:~Pregnant or breastfeeding. Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality.~History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis or kidney disease(s), diabetes, or autoimmune disease.~Previous vaccination against human papillomavirus (HPV).

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).